Spyre Therapeutics, Inc.

Contributing Author

Recent Articles by Spyre Therapeutics, Inc.

Nov-04	Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update SYRE GlobeNewswire
Nov-04	Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody SYRE GlobeNewswire
Oct-29	Spyre Therapeutics to Participate in Upcoming November Investor Conferences SYRE GlobeNewswire
Oct-24	Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 SYRE GlobeNewswire
Oct-15	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million SYRE GlobeNewswire
Oct-13	Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock SYRE GlobeNewswire
Oct-13	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants SYRE GlobeNewswire
Oct-05	Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 SYRE GlobeNewswire
Oct-03	Spyre Therapeutics Announces Grants of Inducement Awards SYRE GlobeNewswire
Sep-15	Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases SYRE GlobeNewswire